Compare Medpace Holdings Inc (MEDP) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Verisign, Inc. — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Verisign, Inc. trades at $276.51 (market cap $25.26B). The key difference: Verisign, Inc. is the larger of the two by market cap, and Verisign, Inc. pays a 1.17% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | VRSN | |
|---|---|---|
Market Cap | $15.08B | $25.26B |
Sector | Technology | Technology |
52-Week High | $620.59 | $310.00 |
52-Week Low | $308.88 | $211.49 |
Enterprise Value | $14.55B | $26.50B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
VeriSign (VRSN) trades at $277.60, down slightly by 0.02% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with EPS of $2.34 beating estimates, driven by 6.6% revenue growth. Analyst consensus is a Buy with a $325.25 price target, reflecting confidence in its domain registry monopoly and robust margins.
Outlook remains positive due to predictable revenue streams from .com and .net domains, though risks include AI disruption and contract renewals. Valuation multiples like P/E of 30.68 appear elevated, requiring sustained growth to justify. Investors should weigh high margins against debt levels and competitive threats for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
